Results 51 to 60 of about 73,979 (245)

Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report

open access: yesSAGE Open Medical Case Reports
Vitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo.
Seyyon Satkunanathan   +3 more
doaj   +1 more source

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

open access: yesClinical and Experimental Gastroenterology, 2023
Malcolm Irani,1 Christopher Fan,1 Kerri Glassner,1– 3 Bincy P Abraham1– 3 1Houston Methodist Gastroenterology Associates, Houston Methodist Hospital, Houston, TX, USA; 2Weill Cornell Medical College, New York, NY, USA; 3Houston Methodist Academic ...
Irani M, Fan C, Glassner K, Abraham BP
doaj  

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

open access: yesSAGE Open Medical Case Reports, 2023
Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj   +1 more source

Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3‐CXCL8 Axis

open access: yesAdvanced Science, EarlyView.
A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Weihui Guo   +8 more
wiley   +1 more source

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

open access: yesNature Communications, 2021
Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes.
Sarfaraz A. Hasni   +38 more
doaj   +1 more source

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

open access: yesAdvanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie   +14 more
wiley   +1 more source

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report

open access: yesSAGE Open Medical Case Reports, 2022
This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient.
Adrienn N Bourkas, Cathryn Sibbald
doaj   +1 more source

Network pharmacology-based approach to explore the underlying mechanism of sinomenine on sepsis-induced myocardial injury in rats

open access: yesFrontiers in Pharmacology, 2023
Background: Sepsis, a systemic disease, usually induces myocardial injury (MI), and sepsis-induced MI has become a significant contributor to sepsis-related deaths in the intensive care unit.
Linggang Sun   +3 more
doaj   +1 more source

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

open access: yesAdvanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li   +6 more
wiley   +1 more source

Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study

open access: yesActa Dermato-Venereologica
The European Medicines Agency recently limited the use of oral Janus kinase inhibitors in certain patient populations, including those with atopic dermatitis.
Ida Vittrup   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy